Adicet Bio Added to the Russell 2000® Index
28 Giugno 2021 - 1:00PM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced that the Company has
been added to the Russell 2000® Index, effective June 28, 2021, as
part of the 2021 Russell indexes annual reconstitution.
"Adicet’s inclusion in the US small-cap Russell 2000 Index
reflects the meaningful progress we have made over the past year,
and we believe it will help broaden awareness of our differentiated
pipeline of ‘off-the-shelf’ gamma delta T cell product candidates
for the treatment of solid and hematologic tumors,” said Chen
Schor, President and Chief Executive Officer of Adicet Bio. “We
continue to build momentum and look forward to reporting interim
clinical data from the Phase 1 study of ADI-001, our lead
candidate, later this year.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in
assets are benchmarked against Russell’s US indexes. Russell
indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell indexes reconstitution, go
to the “Russell Reconstitution” section on the FTSE Russell
website.
About Adicet Bio, Inc.Adicet Bio, Inc. is a
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for cancer and other diseases. Adicet is
advancing a pipeline of “off-the-shelf” gamma delta T cells,
engineered with chimeric antigen receptors and T cell receptor-like
antibodies to enhance selective tumor targeting, facilitate innate
and adaptive anti-tumor immune response, and improve persistence
for durable activity in patients. For more information, please
visit our website at http://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet
including, but not limited to, express or implied statements
regarding the potential benefits resulting from the inclusion in
the US small-cap Russell 2000 Index to our business or strategy,
and preclinical and clinical development of Adicet’s product
candidates and timing of interim clinical data from Adicet’s Phase
1 study of ADI-001. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
of future events, and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements, including without limitation, the
effect of COVID-19 on Adicet’s business and financial results,
including with respect to disruptions to its clinical trials and
business operations; future clinical studies may fail to
demonstrate adequate safety and efficacy of our product candidates,
which would prevent, delay, or limit the scope of regulatory
approval and commercialization; regulatory approval processes of
the FDA and comparable foreign regulatory authorities are lengthy,
time-consuming, and inherently unpredictable; as well as those
risks and uncertainties set forth in Adicet’s most recent quarterly
report on Form 10-Q and subsequent filings with the Securities and
Exchange Commission (SEC). For a discussion of these and other
risks and uncertainties, and other important factors, any of which
could cause Adicet’s actual results to differ from those contained
in the forward-looking statements, see the section entitled “Risk
Factors” in Adicet’s most recent annual report on Form 10-K and
periodic reports on Form 10-Q and Form 8-K filed with the SEC, as
well as discussions of potential risks, uncertainties, and other
important factors in Adicet’s other filings with the SEC. All
information in this press release is as of the date of the release,
and Adicet undertakes no duty to update this information unless
required by law.
Adicet Bio., Inc.Investor and Media
Contacts
Anne Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Lug 2023 a Lug 2024